Placeholder

Biotech’s Perfect Storm

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 357. Category: .

Product Description

Biotechnology companies have come into their own. A report from Ernst & Young finds U.S. biotech companies rebounded in dramatic fashion in 2003 and 2004 from a precipitous stock market decline that had left many companies facing severe cash shortages and feeling desperate about the future. The major force driving this resurgence is biotech companies’ success in moving new, first-in-class medicines through clinical trials and into the market. Ernst & Young predicts the industry should achieve net income for the first time in its 30-year history in 2008.
The growth of the biotech industry will continue to outpace that of pharmaceutical companies, with the seven largest biotechnology companies growing at rates faster than the pharmaceutical industry’s 9.1% average, according to Wood Mackenzie.
Ernst & Young researchers say the biotech industry has moved from technology-driven to product-driven, from potential to performance. This shift from being a technology to product industry, which has been ongoing since the debut of biotech companies 30 years ago, has accelerated in recent years…

Sidebars:
Biotechnology Industry Facts
The Future of Biogenerics
Biotechnology Advances Have Improved R&D Success Rates
Burrill & Co.’s Outlook for 2005
Biotech Market Capitalization 1997-2004
Venture Capital Investing Settles Back to $4.6 Billion in First-Quarter 2005
Becoming a “Partner of Choice”
Geographic Excellence
States Are Tapping Bioscience Specialties to Fuel Economies

Thought Leaders
Roger Attick. CEO and President, CeMines, Golden, Colo.; CeMines is a biotechnology company that applies principles of gene regulation to develop diagnostics and directed therapeutics for cancer. For more information, visit cemines.com.
Martina Cartwright. VP of Scientific Affairs and Development, ImmuneRegen BioSciences Inc., Scottsdale, Ariz.; ImmuneRegen is a biotechnology company engaged in the research and development of applications using modified substance P, a naturally occurring immunomodulator. For more information, visit immuneregen.com.
Bassil I. Dahiyat, Ph.D. President and CEO, Xencor Inc., Monrovia, Calif.; Xencor is a privately held biopharmaceutical company focused on the discovery and development of protein therapeutics for the treatment of cancer, inflammation, and autoimmune disorders. For more information, visit xencor.com.
Lisa N. Drakeman, Ph.D. President and CEO, Genmab Inc., Princeton, N.J.; Genmab A/S, with global headquarters in Copenhagen, Denmark, is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. For more information, visit genmab.com.
Michele Garufi. Chairman and CEO, NicOx S.A., Sophia Antipolis, France; NicOx is an emerging pharmaceutical company involved in the research and development of nitric oxide-donating drugs in the inflammation, pain, and cardiovascular therapeutic areas. For more information, visit nicox.com.
Dennis I. Goldberg, Ph.D. President and Chief Operating Officer, Transport Pharmaceuticals Inc., Framingham, Mass.; Transport Pharmaceuticals is a developer of electrical-based technology for transdermal drug delivery. For more information visit transportpharma.com.
Julia P. Gregory. Executive VP, Corporate Development and Chief Financial Officer, Lexicon Genetics Inc., The Woodlands, Texas; Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. For more information, visit lexicon-genetics.com.
Saul Komisar. President, Protherics Inc., Brentwood, Tenn.; Protherics is a subsidiary of Protherics Plc., a vertically integrated biotechnology company focused on developing and marketing oncology and critical-care products. For more information, visit protherics.com.
Daniel L. Korpolinski. Director, and Former President, and CEO, Stressgen Biotechnologies Corp., Victoria, British Columbia, Canada; Stressgen is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutic vaccines for the treatment of infectious diseases and cancer. For more information, visit stressgen.com.
Hans J. M├Ąder. President and CEO, Procyon Biopharma Inc., Dorval, Quebec, Canada; Procyon is a biotechnology company actively engaged in the development of innovative therapeutics in the fields of cancer and HIV/AIDS. For more information, visit procyonbiopharma.com.
Jeff Morhet. Chief Operating Officer, InNexus Biotechnology Inc., Vancouver, British Columbia, Canada; InNexus is an innovative antibody-driven drug development company that has developed two technology platforms, SuperAntibody and TransMAbs, which improve the potency of existing antibody products while opening new markets and disease applications. For more information, visit innexusbiotech.com.
Ricardo Moro-Vidal, M.D. President and CEO, BioCurex Inc., Richmond, British Columbia, Canada; BioCurex is a biotechnology company that is developing products based on patented/proprietary technology in the area of cancer diagnosis, imaging,and therapy. For more information, visit biocurex.com.
Raul R. Rodriguez. Executive VP, and Chief Operating Officer, Rigel Pharmaceuticals Inc., South San Francisco, Calif.; Rigel is developing novel, small-molecule drugs to address large, unmet medical needs. For more information, visit rigel.com.
Morrie Ruffin. Executive VP, Business Development and Emerging Companies, The Biotechnology Industry Organization, Washington, D.C.; BIO represents more than 1,100 biotech companies, academic institutions, state biotech centers, and related organizations in all 50 U.S. states and 33 other nations. For more information, visit bio.org.
M. Scott Salka. CEO, Ambit Biosciences, San Diego; Ambit Biosciences is a privately held biopharmaceutical company developing small-molecule neuroprotectants for the treatment of stroke and other CNS disorders and kinase inhibitors for the treatment of cancer and inflammation. For more information, visit ambitbio.com.
Brian P. Zambrowicz, Ph.D. Executive VP, Research, Lexicon Genetics Inc., The Woodlands, Texas; Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. For more information, visit lexicon-genetics.com.

FEEDBACK